PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jmedtoxspringer.comThis journalToc AlertsSubmit OnlineOpen ChoiceThis journal
 
J Med Toxicol. 2010 September; 6(3): 307–310.
Published online 2010 April 1. doi:  10.1007/s13181-010-0017-6
PMCID: PMC2929436

A Retrospective Review of Supratherapeutic Modafinil Exposures

Abstract

Modafinil is a non-amphetamine wakefulness-promoting agent used for the treatment of various sleep disorders characterized by excessive daytime sleepiness. There is little information in the medical literature with respect to supratherapeutic doses of this medication. We performed a retrospective review of the California Poison Control System database for all cases of single-substance ingestion of modafinil with follow-up to a known outcome for the time period 1998–2008. Data collected included age, gender, dose ingested, clinical effects, and medical outcome. There were a total of 87 patients, 53 (61%) of which were female. Patient ages ranged from 1.25 to 72 years with a mean of 30 years; 17 (20%) patients were aged 6 years or less. Thirty-three (38%) were intentional overdoses. Most commonly reported effects were tachycardia (n = 23), agitation (n = 14), anxiety (n = 11), headache (n = 8), hypertension (n = 6), dystonia/tremor (n = 6), and dizziness (n = 5). Forty-nine patients (56%) were managed at home, and 38 (44%) were managed in a healthcare setting. Therapies administered included activated charcoal (n = 8), benzodiazepines (n = 7), antihistamines (n = 2), intravenous fluids (n = 2), haloperidol (n = 2), and beta-blockers (n = 1). Effects were classified as none (n = 22), minor (n = 54), and moderate (n = 11). No major effects and no deaths occurred. Effects of modafinil overdose appear to be mild in most cases, with tachycardia and CNS symptoms predominating. Clinically significant effects requiring treatment occurred in a small number of patients.

Keywords: Modafinil, Poisoning, Overdose

Full Text

The Full Text of this article is available as a PDF (108K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol. 2009;256:645–650. doi: 10.1007/s00415-009-0152-7. [PubMed] [Cross Ref]
2. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76:1636–1639. doi: 10.1136/jnnp.2005.065870. [PMC free article] [PubMed] [Cross Ref]
3. Rabkin JG, McElhiney MC, Rabkin R, Ferrando SJ. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry. 2004;65:1688–1695. doi: 10.4088/JCP.v65n1215. [PubMed] [Cross Ref]
4. Blackhall L, Petroni G, Shu J, Baum L, Farace E. A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. J Palliat Med. 2009;12:433–439. doi: 10.1089/jpm.2008.0230. [PubMed] [Cross Ref]
5. Pachas WN. Modafinil for the treatment of fatigue of fibromyalgia. J Clin Rheumatol. 2003;9:282–285. doi: 10.1097/01.RHU.0000081255.66597.df. [PubMed] [Cross Ref]
6. Dackis C, O’Brien C. Glutamatergic agents for cocaine dependence. Ann NY Acad Sci. 2003;1003:328–345. doi: 10.1196/annals.1300.021. [PubMed] [Cross Ref]
7. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O’Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005;30:205–211. doi: 10.1038/sj.npp.1300600. [PubMed] [Cross Ref]
8. Dackis CA, Lynch KG, Yu E, Samaha FF, Kampman KM, Cornish JW, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 2003;70:29–37. doi: 10.1016/S0376-8716(02)00335-6. [PubMed] [Cross Ref]
9. Saletu B, Saletu M, Grünberger J, Frey R, Zatschek I, Mader R. On the treatment of the alcoholic organic brain syndrome with an alpha-adrenergic agonist modafinil: double-blind, placebo-controlled clinical, psychometric and neurophysiological studies. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:195–214. doi: 10.1016/0278-5846(90)90101-L. [PubMed] [Cross Ref]
10. Saletu B, Saletu M, Grünberger J, Frey R, Anderer P, Mader R. Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neuropsychobiology. 1993;27:26–39. doi: 10.1159/000118950. [PubMed] [Cross Ref]
11. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61:378–381. doi: 10.4088/JCP.v61n0510. [PubMed] [Cross Ref]
12. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33:1477–1502. doi: 10.1038/sj.npp.1301534. [PubMed] [Cross Ref]
13. Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther. 2006;319:561–569. doi: 10.1124/jpet.106.106583. [PubMed] [Cross Ref]
14. Simon P, Hémet C, Ramassamy C, Costentin J. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol. 1995;5:509–514. doi: 10.1016/0924-977X(95)00041-M. [PubMed] [Cross Ref]
15. De Séréville JE, Boer C, Rambert FA, Duteil J. Lack of pre-synaptic dopaminergic involvement in modafinil activity in anaesthetized mice: in vivo voltammetry studies. Neuropharmacology. 1994;33:755–761. doi: 10.1016/0028-3908(94)90115-5. [PubMed] [Cross Ref]
16. Lackey GD, Alsop JA, Albertson TE. A 24 month retrospective study of adult modafinil ingestions. Clin Toxicol (Phila) 2007;45:641.
17. Lackey GD, Alsop JA, Sands TR, Albertson TE. A two year retrospective study of pediatric modafinil ingestions. Clin Toxicol (Phila) 2007;45:643.
18. Spiller HA, Borys D, Griffith JR, Klein-Schwartz W, Aleguas A, Sollee D, et al. Toxicity from modafinil ingestion. Clin Toxicol (Phila) 2009;47:153–156. [PubMed]
19. Physicians’ Desk Reference (2003) Package insert for Provigil. Thomson PDR, Montvale, NJ
20. Bronstein AC, Spyker DA, Cantilena LR, Jr, Green JL, Rumack BH, Heard SE, et al. 2007 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 25th annual report. Clin Toxicol (Phila) 2008;46:927–1057. [PubMed]
21. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance—a review of abuse liability issues. Ann Clin Psychiatry. 2004;16:101–109. [PubMed]
22. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301:1148–1154. doi: 10.1001/jama.2009.351. [PMC free article] [PubMed] [Cross Ref]
23. Erowid.org. Erowid vault: modafinil (cited 2009 Jun 2). Available from: http://www.erowid.org/smarts/modafinil/modafinil.shtml

Articles from Journal of Medical Toxicology are provided here courtesy of Springer